Pneumonia risk in diabetic patients to be reduced by SGLT2 inhibitors
Diabetic patients are 3 times more likely to die with flu and pneumonia. Yet, only one third of them ever get a simple, safe pneumonia shot. Pneumonia is a serious illness for anyone, but highly riskier with a history of diabetics.
Patients with type 2 diabetes using SGLT2 inhibitors are at a significantly lower risk of pneumonia and pneumonia mortality versus those using DPP4 Iinhibitors, reveals a reent study. The study was published in the Journal of Clinical Endocrinology and Metabolism on 08 November 2021.
Sodium glucose co-transporter 2 inhibitors (SGLT2is) are the latest class of glucose-lowerinf agents that have shown to reduce pneumonia risk in clinical trials. However, not much is known about the real-world effectiveness of SGLT2is on the risk of pneumonia.
To determine the same, Ching-Lung Cheung, The University of Hong Kong, Hong Kong SAR, China, and the team aimed to investigate the associations between SGLT2is use and the risk of pneumonia and pneumonia mortality versus dipeptidyl peptidase-4 inhibitors (DPP4is) using an electronic medical database in Hong Kong in a retrospective cohort study.
For more information check out the full story on the link below:
SGLT2 inhibitors use tied to lower pneumonia risk in diabetics: Study
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.